S&P Futures
4,263.75 -17.25 (-0.40%) Dow Futures
33,607.00 -111.00 (-0.33%) Nasdaq Futures
13,513.75 -64.00 (-0.47%) Russell 2000 Futures
2,007.30 -9.60 (-0.48%) Crude Oil
91.02 -1.07 (-1.16%) Gold
1,798.00 -0.60 (-0.03%)
Virios Therapeutics, Inc. (VIRI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.69 |
| Open | 7.75 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 2200 |
| Day's Range | 7.51 - 8.86 |
| 52 Week Range | 3.30 - 8.86 |
| Volume | |
| Avg. Volume | 20,758 |
| Market Cap | 72.474M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.38 |
| Earnings Date | Aug 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.00 |
- Business Wire
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
ATLANTA, August 11, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the second quarter ended June 30, 2022.
- Business Wire
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
ATLANTA, August 10, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Q3 Virtual Investor Summit. During the presentation, the Company will provide an overview of its business and corporate strategy as well as upcoming key
- Newsfile
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Company's September Phase 2b trial results could be transformative for fibromyalgia patients New York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and dev
